Lisa B.’s Post

The pace of trial recruitment for Alzheimer's disease is lagging behind scientific advancements, particularly in early-phase clinical trials. Parexel experts Lydia Morris and Jakki James emphasize the significance of listening to and engaging with the concerns of prospective trial participants. They also propose innovative solutions for earlier diagnoses and the identification of surrogates for patients. Read the latest blog from our neurosciences trial series here: https://lnkd.in/dwe3pCcZ Message me if you would like to learn more about how Parexel is increasing efficiencies in clinical trial participation! #Alzheimers #EarlyPhase #ClinicalResearch #PatientsFirst

The pace of trial recruitment for Alzheimer's disease is lagging behind scientific advancements, particularly in early-phase clinical trials. Parexel experts Lydia Morris and Jakki James emphasize the significance of listening to and engaging with the concerns of prospective trial participants. They also propose innovative solutions for earlier diagnoses and the identification of surrogates for patients. Read the latest blog from our neurosciences trial series here: https://lnkd.in/e24D4fRc Message me if you would like to learn more about how Parexel is increasing efficiencies in clinical trial participation! #Alzheimers #EarlyPhase #ClinicalResearch #PatientsFirst

The pace of trial recruitment for Alzheimer's disease is lagging behind scientific advancements, particularly in early-phase clinical trials. Parexel experts Lydia Morris and Jakki James emphasize the significance of listening to and engaging with the concerns of prospective trial participants. They also propose innovative solutions for earlier diagnoses and the identification of surrogates for patients. Read the latest blog from our neurosciences trial series here: https://lnkd.in/eWV7V-yB Message me if you would like to learn more about how Parexel is increasing efficiencies in clinical trial participation! #Alzheimers #EarlyPhase #ClinicalResearch #PatientsFirst

The pace of trial recruitment for Alzheimer's disease is lagging behind scientific advancements, particularly in early-phase clinical trials. Parexel experts Lydia Morris and Jakki James emphasize the significance of listening to and engaging with the concerns of prospective trial participants. They also propose innovative solutions for earlier diagnoses and the identification of surrogates for patients. Read the latest blog from our neurosciences trial series here: https://lnkd.in/euQG5nGh Message me if you would like to learn more about how Parexel is increasing efficiencies in clinical trial participation! #Alzheimers #EarlyPhase #ClinicalResearch #PatientsFirst

The pace of trial recruitment for Alzheimer's disease is lagging behind scientific advancements, particularly in early-phase clinical trials. Parexel experts Lydia Morris and Jakki James emphasize the significance of listening to and engaging with the concerns of prospective trial participants. They also propose innovative solutions for earlier diagnoses and the identification of surrogates for patients. Read the latest blog from our neurosciences trial series here: https://lnkd.in/g3kG8jj3 Message me if you would like to learn more about how Parexel is increasing efficiencies in clinical trial participation! #Alzheimers #EarlyPhase #ClinicalResearch #PatientsFirst

The pace of trial recruitment for Alzheimer's disease is lagging behind scientific advancements, particularly in early-phase clinical trials. Parexel experts Lydia Morris and Jakki James emphasize the significance of listening to and engaging with the concerns of prospective trial participants. They also propose innovative solutions for earlier diagnoses and the identification of surrogates for patients. Read the latest blog from our neurosciences trial series here: https://lnkd.in/evpCcJjX Message me if you would like to learn more about how Parexel is increasing efficiencies in clinical trial participation! #Alzheimers #EarlyPhase #ClinicalResearch #PatientsFirst

The pace of trial recruitment for Alzheimer's disease is lagging behind scientific advancements, particularly in early-phase clinical trials. Parexel experts Lydia Morris and Jakki James emphasize the significance of listening to and engaging with the concerns of prospective trial participants. They also propose innovative solutions for earlier diagnoses and the identification of surrogates for patients. Read the latest blog from our neurosciences trial series here: https://lnkd.in/gSTFhQbQ Message me if you would like to learn more about how Parexel is increasing efficiencies in clinical trial participation! #Alzheimers #EarlyPhase #ClinicalResearch #PatientsFirst

The pace of trial recruitment for Alzheimer's disease is lagging behind scientific advancements, particularly in early-phase clinical trials. Parexel experts Lydia Morris and Jakki James emphasize the significance of listening to and engaging with the concerns of prospective trial participants. They also propose innovative solutions for earlier diagnoses and the identification of surrogates for patients. Read the latest blog from our neurosciences trial series here: https://lnkd.in/gD7qVKMh Message me if you would like to learn more about how Parexel is increasing efficiencies in clinical trial participation! #Alzheimers #EarlyPhase #ClinicalResearch #PatientsFirst

The pace of trial recruitment for Alzheimer's disease is lagging behind scientific advancements, particularly in early-phase clinical trials. Parexel experts Lydia Morris and Jakki James emphasize the significance of listening to and engaging with the concerns of prospective trial participants. They also propose innovative solutions for earlier diagnoses and the identification of surrogates for patients. Read the latest blog from our neurosciences trial series here: https://lnkd.in/e_63xRJv Message me if you would like to learn more about how Parexel is increasing efficiencies in clinical trial participation! #Alzheimers #EarlyPhase #ClinicalResearch #PatientsFirst

The pace of trial recruitment for Alzheimer's disease is lagging behind scientific advancements, particularly in early-phase clinical trials. Parexel experts Lydia Morris and Jakki James emphasize the significance of listening to and engaging with the concerns of prospective trial participants. They also propose innovative solutions for earlier diagnoses and the identification of surrogates for patients. Read the latest blog from our neurosciences trial series here: https://lnkd.in/dau7YstB Message me if you would like to learn more about how Parexel is increasing efficiencies in clinical trial participation! #Alzheimers #EarlyPhase #ClinicalResearch #PatientsFirst